Continued enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Announced key appointments and advancements in leadership team Ended second quarter 2022 with $397.6 million in cash and equivalents Cash runway extended into second half of 2025 WALTHAM, Mass. , Aug.

WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Bruce Rogers, Ph.D., President of Morphic, will give a

Experienced Regulatory Leader with Record of Global and Regulatory Success Across Multiple Therapeutic Areas WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of

WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will participate in a fireside

WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced two key executive appointments. Dr.

Initiated EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis   Described new understanding of α4β7-expressing immune cells and MORF-057 dose response in oral presentation at ECCO 2022 Announced key appointments and advancements in leadership team Ended first quarter 2022 with

Dr. Brihad Abhyankar named Vice President of Clinical Development, deeply experienced GI drug development leader Aaron Pelta promoted to Senior Vice President, Business and Corporate Development; leading portfolio, commercial, and partnering strategy WALTHAM, Mass., April 06, 2022 (GLOBE NEWSWIRE)

WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced Morphic COO and CFO Marc Schegerin, M.D.

MORF-057, an oral α4β7 integrin inhibitor candidate, holds potential for treating inflammatory bowel diseases Phase 2b EMERALD-2 clinical trial of MORF-057 expected to begin mid-year 2022 WALTHAM, Mass., March 25, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), today announced the

WALTHAM, Mass., March 04, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced Morphic President and CEO Praveen Tipirneni, M.D.